Table 4 Clinical characteristics by accurately versus inaccurately reported ‘well-controlled’, asthma.

From: A multinational observational study identifying primary care patients at risk of overestimation of asthma control

 

Patient reported ‘well-controlled’ asthma (N = 2582)

p Value*

 

Group A

Group B

 
 

Accurately reported (n = 745)

Inaccurately reported (n = 1837)

 

Patient-reported rhinitis symptoms, n (%)

480 (64.4)

1194 (65.1)

0.75a

Patient-reported prior inhaler review by HCPb, n (%)

348 (46.7)

1027 (56.0)

<0.001a

Patient self-assessment of inhaler technique, n (%), known

(n = 730)

(n = 1816)

 

Very poor to poor

42 (5.8)

106 (5.8)

0.17a

Fair to average

94 (12.9)

287 (15.8)

Good to excellent

594 (81.4)

1423 (78.4)

Patient-reported respiratory specialist review

(n = 620)

(n = 1693)

 

Never

242 (39.0)

430 (25.4)

<0.001a

In the previous year

107 (17.3)

230 (13.6)

More than a year ago

271 (43.7)

1033 (61.0)

Adherence to therapyc, n (%)

(n = 724)

(n = 1794)

 

Poor

219 (30.2)

569 (31.7)

0.70a

Borderline

45 (6.2)

101 (5.6)

Good

460 (63.5)

1124 (62.7)

Adherence to therapy in the Netherlandsd, n (%), known

(n = 22)

(n = 49)

 

Poor

7 (31.8)

5 (10.2)

0.06a

Borderline

5 (22.7)

9 (18.4)

Good

10 (45.5)

35 (71.4)

Patient-reported side effectse, n (%), known

(n = 721)

(n = 1793)

 

None

507 (70.3)

903 (50.4)

<0.001a

1

146 (20.2)

434 (24.2)

2

52 (7.2)

276 (15.4)

≥3

16 (2.2)

180 (10.0)

Patient-reported oropharyngeal effectsg, n (%) known

(n = 711)

(n = 1766)

 

None

452 (63.6)

837 (47.4)

<0.001a

1

137 (19.3)

444 (25.1)

2

88 (12.4)

275 (15.6)

3

34 (4.8)

210 (11.9)

Agreement to medication beliefs/perception items, n (%) known

(n = 721)

(n = 1796)

 

I need to take my inhaler(s) for my asthma to be well-controlled

460 (63.8)

1273 (70.9)

0.001a

I find my inhaler easy to use

649 (90.0)

1616 (90.0)

0.98a

Taking regular asthma medication does not worry me

563 (78.1)

1422 (79.2)

0.55a

  1. HCP health care practitioner
  2. *p Value of Group A versus Group B
  3. a Pearson’s χ2 test for independence
  4. bIn the year before an iHARP asthma review
  5. cNumber (%) calculated as percentage of patients from the UK, Italy, Spain, Sweden, France and Norway reported as n (%) of known status
  6. dNumber (%) calculated as percentage of patients from the Netherlands
  7. ePatient-reported side effects from preventer inhaler use, in response to the question: ‘Do you experience any of these side effects from your preventer inhaler?’ with ‘yes’ or ‘no’ responses for the following side effects: continual sore mouth/throat; oral thrush; bruising; hoarse voice; abnormal weight gain and cough. Patients could indicate more than one side effect
  8. fPatient-reported oropharyngeal effects during inspiration phase of preventer inhaler use, in response to the question: ‘When you use your preventer inhaler, do you feel a sensation at the back of your throat?; do you sometimes feel a need to cough?; do you feel your medication is deposited at the back of your throat?’ with yes’ or ‘no’ response options. Patients could indicate more than one experience
Back to article page